-
Tesla global auto sales jump 25% in 2nd quarter, beating expectations
-
Superb Swiatek, Zverev cruise into Wimbledon last 32
-
Zverev routs Royer to reach Wimbledon third round
-
Ukraine, Russia vow escalation after Moscow attack kills 21 in Kyiv
-
Hot spell roasts eastern US ahead of holiday weekend
-
Slowing US job growth poses midterms challenge for Trump
-
Hamilton cools fans Ferrari fervour
-
Klopp poised to replace Nagelsmann as Germany coach: reports
-
Venezuela's diaspora searches for quake victims on social media
-
More than 400 dead in DR Congo's spreading Ebola outbreak
-
Albanian clashes as protest over Trump-linked resort boils over
-
Hot spell roasts eastern US as holiday weekend approaches
-
Desire key to Pogacar dominance, says former Tour king Froome
-
Superb Swiatek storms into Wimbledon last 32, Zverev waits
-
Rescuers dig out Venezuelan man eight days after quakes
-
Russian strikes kill 21 in biggest ever attack on Kyiv, mayor says
-
Anderson closes in on record Man City move
-
Swiatek sees off Pliskova to race into Wimbledon third round
-
England change five for South Africa Test
-
Dollar down, stocks shine after disappointing US jobs data
-
Lock Alemanno to make 100th Pumas appearance against Scotland
-
US job growth slows, posing questions for Trump before midterms
-
US posts weaker-than-expected job growth in June
-
Chanel eyes menswear with Charvet shirtmaker takeover
-
UK PM says 'deeply sorry' for decades of forced adoptions
-
Chanel eyes menswear with Charvet shirtmaker takevoer
-
Almost 1.2 mn apply for Spain's migrant regularisation
-
'I grabbed my child': Kyiv residents face devastation of biggest Russian barrage of war
-
Ukrainian state ordered Nord Stream sabotage: German prosecutors
-
Former top jockey Dettori breaks ribs in car crash
-
Swiatek, Zverev aiming to lay down Wimbledon markers
-
Rees-Zammit returns to wing as Wales face Fiji
-
German ruling coalition agrees on major reform package
-
Renovations on historic Paris Opera house extended by three years
-
European stocks climb after Asia rout
-
Thailand denies viral claim Macron knelt before king
-
Former Arsenal, Spain midfielder Cazorla retires
-
Spain, Portugal eye World Cup last 16
-
German drone maker raises $1.2 bn as investors pile into defence
-
Russian strikes kill 17 in biggest ever attack on Kyiv, mayor says
-
French scramble to find air conditioners before next heatwave
-
Uruguay veteran Cavani quits Boca Juniors
-
Japan deploys bear cameras in moutains as attacks surge
-
West Ham's Fernandes joins Spurs
-
Germany's Infineon opens major chip plant as EU seeks tech autonomy
-
Bones of contention: More research needed on 'd'Artagnan corpse'
-
Biggest ever Russian barrage on Kyiv kills at least 13
-
Coffee with a view: tourists flock to Starbucks overlooking North Korea
-
EU top court upholds record 4.1 bn euro Google fine
-
German coalition agrees on reform package in key breakthrough
US cracks down on 'tranq' drug linked to fatal overdoses
The United States announced Tuesday a crackdown on unlawful imports of xylazine, an animal tranquilizer known as the "zombie drug" and which is increasingly linked to overdose deaths.
Xylazine, which also goes by the street name "tranq," has recently been found in illicitly manufactured fentanyl, heroin, cocaine and other drugs, presenting a "growing public health concern," the Food and Drug Administration (FDA) said.
"This action aims to prevent the drug from entering the US market for illicit purposes, while maintaining availability for its legitimate uses in animals," it said in a statement.
According to the National Institute on Drug Abuse, the percentage of all drug overdose deaths involving xylazine increased from two percent to 26 percent in the northeast state of Pennsylvania from 2015 to 2020.
Xylazine is typically used by veterinarians to sedate large animals such as horses and deer but the drug is not approved for use in humans.
It can slow breathing, blood pressure and heart rate to critically low levels and cause skin ulcers and abscesses that can lead to amputation.
The FDA said imports of xylazine would be subject to heightened scrutiny and seized if they appear to be unlawful.
"The FDA remains concerned about the increasing prevalence of xylazine mixed with illicit drugs, and this action is one part of broader efforts the agency is undertaking to address this issue," FDA commissioner Robert Califf said.
N.Fournier--BTB